Opportunities for Outpatient Pharmacy Services for Patients with Cystic Fibrosis: Perceptions of Healthcare Team Members

Abstract

Cystic fibrosis (CF) is one of the most common life-threatening, genetic conditions. People with CF follow complex, time-consuming treatment regimens to manage their chronic condition. Due to the complexity of the disease, multidisciplinary care from CF Foundation (CFF)-accredited centers is recommended for people with CF. These centers include several types of healthcare professionals specializing in CF; however, pharmacists are not required members. The purpose of this study was to identify the outpatient care needs of people living with CF that pharmacists could address to improve their quality of care. Healthcare members from a CFF accredited center and pharmacists were recruited to participate in semi-structured, audio-recorded interviews. Prevalent codes were identified and data analysis was conducted, guided by the systems engineering initiative for patient safety (SEIPS) model. The objective was to understand the medication and pharmacy-related needs of patients with CF and care team perspectives on pharmacists providing support for these patients. From the themes that emerged, pharmacists can provide support for people living with CF (medication burden, medication access, medication education) and the CF care team (drug monitoring and adherence, prior authorizations and insurance coverage, refill history). Pharmacists are well-positioned to address these difficulties to improve quality of care for people living with cystic fibrosis.

Full text

Pharmacy 2019, 7, 34; doi:10.3390/pharmacy7020034 www.mdpi.com/journal/pharmacy
Article
Opportunities for Outpatient Pharmacy Services for
Patients with Cystic Fibrosis: Perceptions of
Healthcare Team Members
Olufunmilola Abraham * and Ashley Morris
Social and Administrative Sciences Division, University of Wisconsin-Madison School of Pharmacy,
Madison, WI 53705, USA; amorris4@wisc.edu
* Correspondence: olufunmilola.abraham@wisc.edu; Tel.: +1-608-263-4498
Received: 27 February 2019; Accepted: 27 March 2019; Published: 3 April 2019
Abstract: Cystic fibrosis (CF) is one of the most common life-threatening, genetic conditions. People
with CF follow complex, time-consuming treatment regimens to manage their chronic condition.
Due to the complexity of the disease, multidisciplinary care from CF Foundation (CFF)-accredited
centers is recommended for people with CF. These centers include several types of healthcare
professionals specializing in CF; however, pharmacists are not required members. The purpose of
this study was to identify the outpatient care needs of people living with CF that pharmacists could
address to improve their quality of care. Healthcare members from a CFF accredited center and
pharmacists were recruited to participate in semi-structured, audio-recorded interviews. Prevalent
codes were identified and data analysis was conducted, guided by the systems engineering initiative
for patient safety (SEIPS) model. The objective was to understand the medication and pharmacy-
related needs of patients with CF and care team perspectives on pharmacists providing support for
these patients. From the themes that emerged, pharmacists can provide support for people living
with CF (medication burden, medication access, medication education) and the CF care team (drug
monitoring and adherence, prior authorizations and insurance coverage, refill history). Pharmacists
are well-positioned to address these difficulties to improve quality of care for people living with
cystic fibrosis.
Keywords: cystic fibrosis; pharmacists; pharmacy services, medication management; medication
use burden
1. Introduction
Cystic fibrosis (CF) is one of the most prevalent chronic and fatal genetic diseases, affecting
approximately 70,000 people worldwide and 30,000 in the United States alone [1,2]. CF is a
progressive, multisystem disease that primarily affects the respiratory and digestive systems as well
as the pancreas, liver, and reproductive system [1]. CF is an incurable autosomal recessive disorder
caused by mutations in the CF transmembrane conductance regulator (CFTR) [3]. The CFTR
transports chloride and sodium ions in and out of epithelial cells which controls the movement of
water in tissues of the body [4]. Mutations in the CFTR cause thick secretions of mucus to line several
organs in the body such as the lungs, pancreas, digestive system, and reproductive system [4].
Consequently, the thick mucus production puts patients with CF at risk of developing bacterial
infections in the lungs [1]. Although advances in treatment and knowledge of CF have extended the
median predicted survival age to 47.7 years for individuals born in 2016 (compared to age 42.7 years
for those born between 2012 and 2016), patients manage complex, time-consuming, and lifelong
treatment regimens [1,5].

Pharmacy 2019, 7, 34 2 of 16
Medication management with CF is challenging and burdensome. Patients often use eight or
more medications daily with lengthy treatments, such as inhaled antibiotics, that can range 1–3 h
each day [1]. CF medications include CFTR modulators, mucus thinners, bronchodilators, antibiotics,
anti-inflammatories, and pancreatic enzymes [6]. Patients with CF also need to perform airway
clearance techniques which may include the use of a vest and nebulizer treatments [6]. Vest treatment
is a high-frequency chest wall compression therapy that loosens mucus in the lungs and can be
performed in 30-min sessions two to four times per day. Treatment of comorbidities such as
depression, anxiety, and diabetes further complicate CF management [4]. Consequently, CF
medication adherence can be as low as 50%, particularly among children and adolescents [1,7]. Poor
adherence can lead to negative health outcomes such as exacerbations, hospitalizations, and
increased healthcare costs [7].
The complexity of managing CF warrants a multidisciplinary healthcare team. The CF
Foundation (CFF) recommends that patients visit accredited centers with specialized healthcare
professionals at least four times annually [8]. The CFF requires accredited centers to include
healthcare team members such as physicians, nurses, respiratory therapists, dietitians, social
workers, and program coordinators [9]. Pharmacists are only listed as recommended healthcare team
members [9]. However, CF standards of care in countries such as Australia and Britain consider
pharmacists to be vital healthcare team members [10–13]. There has been limited research exploring
how pharmacists in outpatient settings can support people living with CF, which is a missed
opportunity to improve the care of these patients. There is an urgent need to increase access to
pharmacist-provided outpatient care for people with CF to improve their treatment adherence,
medication self-management, and overall health-related quality of life. This study aims to describe
works system characteristics for the pharmacists’ role in caring for patients with cystic fibrosis.
2. Materials and Methods
2.1. Theoretical Framework
The systems engineering initiative for patient safety (SEIPS) 2.0 Model was applied to guide our
understanding of medication management and interactions between pharmacists and other members
of CF healthcare team [14]. The SEIPS model is the most widely used systems engineering framework
for patient and healthcare research and embraces three important principles: (1) A holistic systems-
based approach, (2) person-centeredness, and (3) design-driven improvement needs to be person-
centered to enhance and improve outcomes. The framework proposes the following components of the
work system: Person, organization, tools and technology, environment, and tasks. To explore a
collaborative process in which patients, pharmacists, and other members of the CF healthcare team can
actively engage in medication discussions, it is necessary to understand the activities (or “work”) that
each of these individuals carries out with regard to CF medications.
In the SEIPS framework, person(s) are professional or non-professional individuals and
characteristics of those individuals, like age and expertise. Tasks are specific actions within larger
work processes, with characteristics such as difficulty, complexity, variety, ambiguity, and sequence.
Organizations, in the SEIPS framework, are thought of as structures external to a person put in place
by people that organize time, space, resources, and activity. Tools and technologies are objects that
people use to do work or that assist people in doing work, and is described by usability, accessibility,
familiarity, etc. The SEIPS framework separates environment into two factors: The internal
environment (the physical environment—lighting, noise, temperature, etc.,) and the external
environment, which are economic, ecological, and policy factors outside an organization.
2.2. Setting, Sample, and Recruitment
CF healthcare team member participants were recruited from a CFF-accredited center in an
urban city hospital in Western Pennsylvania. Pharmacists were purposefully recruited from
independent, inpatient, outpatient, and small-chain pharmacies in an urban city in Western
Pennsylvania. The research team worked with the center director to identify study participants. CF

Pharmacy 2019, 7, 34 3 of 16
healthcare member participants declined compensation and pharmacist participants received a $50
incentive. Verbal consent was obtained from study participants. This study was approved by the
University of Pittsburgh Institutional Review Board.
2.3. Data Collection
We conducted key informant interviews with stakeholders integral to the CF medication
management process. The research team developed semi-structured interview guides using open-
ended questions to understand the medication and pharmacy-related issues for people living with
CF. Two members of the research team assessed the interview guides and provided feedback to
ensure content validity. Appendix A contains the guides used to conduct study interviews with
pharmacists and other healthcare team members (such as physicians, nurses, dieticians). A research
assistant conducted 20-min, in-person, and audio-recorded interviews with study participants from
July to September 2016. Participant demographic characteristics such as age, sex, ethnicity, and race
were collected. Interviews were conducted until data saturation was achieved. All interviews were
professionally transcribed verbatim. To ensure study rigor and trustworthiness, pilot-tested
interview guides were used, and reflective journaling and peer debriefing were completed after each
interview.
2.4. Data Analysis
The research team reviewed the transcripts for accuracy. Interview transcripts were analyzed to
develop a list of codes that represented the main conceptual categories within the data. An initial
draft of the codebook was developed by members of the research team. The codebook was later
simplified and refined based on the results of the first two rounds of coding. Coding was carried out
using NVivo10 (QSR International, Melbourne, Australia), a qualitative data analysis software
program that enables multi-coder projects. Interviews were coded by at least one of the coders, with
the two coders overlapping on 12 of the interviews. Disagreements in coding were adjudicated jointly
by the principal investigator and coders. The interview transcripts were coded to identify prevalent
themes. Bi-weekly coding meetings were held to review all codes and resolve any discrepancies. Two
coders coded the interviews to ensure interrater reliability and had an average Kappa score of 0.60.
After the initial coding process, AM conducted deductive content analysis using the categories
described in the work system components of the SEIPS 2.0 theoretical framework. Interview
transcripts were reviewed using the SEIPS 2.0 Model by searching for key words, such as
“pharmacist”, “benefit”, “patient”, “medication”, or “management”. Responses were classified
according to the corresponding work system components of the SEIPS 2.0 model. Within those
components, similar topics and ideas were aggregated into constructs. OA reviewed the application of
the SEIPS 2.0 model to the data to validate the coding. Any discrepancies or differences in opinion
were resolved and consensus was researched before final results were obtained.
3. Results
A total of 22 participants were interviewed, including 8 pharmacists, 6 pulmonologists, 6 nurses,
and 2 dietitians. Of the 22 participants, 12 (55%) were female, 12 (55%) were aged 50 years or older,
21 (95%) were non-Hispanic and White, 7 (32%) had worked 0–10 years, and 7 (32%) had worked 21–
30 years (Table 1). The predominant themes that emerged from this study are discussed within each
of the work system components of the SEIPS 2.0 model [14]. Additional verbatim quotes from study
participants which elaborate on each construct beyond what is provided in the results section is
available in Appendix B.
Table 1. Participant Demographics (n = 22).
Characteristics No. (%)
1
n = 22
Gender
Women 12 (55)

Pharmacy 2019, 7, 34 4 of 16
Men 10 (45)
Age
<30 years 3 (14 1)
30–49 years
7 (32 1)
≥50 years 12 (55 1)
Race
White/Caucasian, Non-Hispanic 21 (95)
White, Hispanic 1 (5)
Role
Nurse
6 (27 1)
Pulmonologist 6 (27 1)
Registered Dietician 2 (9 1)
Pharmacist 8 (36 1)
Years Worked
0–10 years
7 (32)
11–20 years 4 (18)
21–30 years 7 (32)
30+ years 4 (18)
1
Because of rounding, percentage may not total 100.
3.1. Person
Most members of the CF healthcare team have thorough experience working with people with
CF. Pharmacists have variable levels of expertise in CF and in providing services for people with CF.
There is also variation in the setting in which these pharmacists had experience providing service to
people with CF.
Experience and Expertise Caring for People with CF
Pharmacists experience with CF varied: Two pharmacists described providing pharmacy
services to only one to two patients with CF, while three pharmacists reported working with patients
with CF for many years. As pharmacists’ experience working with CF varied, so did their
understanding of the disease. All pharmacists understood healthcare services for patients with CF to
be complex, robust, and requiring of multidisciplinary care, no matter the amount of experience they
reported.
“I’ve dealt with [CF] for like 30 years… From the medication standpoint I think I know pretty much a
lot of what their needs are, for the medications they need, and also the insurance coverage and everything
that I try to do.”—Pharmacist 8
3.2. Tasks
Tasks that participants identified for pharmacists to perform include medication management,
medication education, and medication access.
3.2.1. Medication Management Burden
Any tasks that must be done by patients, members of the CF care team, or pharmacists to
maintain patient compliance to their individual medication regimen or treatment plan are considered
in medication management. All members of the healthcare team and most pharmacists identified a
high treatment burden in people with CF, describing medication management as complex, time-
demanding, confusing, and difficult for the patients in their care. Nurses and pharmacists described
additional medication management burden for the pediatric CF population.
“I think adherence, treatment burden. I mean, our patients can have like an hour and a half of inhale
antibiotics twice to three times a day. Plus, enzymes with each meal and every snack.”—Nurse 1

Pharmacy 2019, 7, 34 5 of 16
“I think a lot of them struggle because they have so many meds to take. I think sometimes it can be
difficult for them to necessarily be motivated to take all their medications.”—Dietician 1
3.2.2. Medication Education
All healthcare professionals rely on and advocate for verbal education between a patient with
CF and each member of the care team. Pharmacists highlight the importance of specialized, one-on-
one counseling, but the frequency by which they believe this counseling should occur and the topics
that should be covered by pharmacists varied. Physicians verbally educate people with CF, but
primarily rely on nurse educators to supplement initial educational conversations. Nurses educate
verbally and provide written materials for people with CF, but describe CF education as a team effort,
including dieticians and respiratory therapists as educators. Nurse educators do not rely on
community pharmacist involvement to educate patients with CF on their medicines. Members of the
existing CF healthcare team highlighted additional educational efforts that needed to be in place for
transition from child to adult care.
“great benefit comes from one on one counseling. We will, as pharmacists here, we will actually get
to a patient’s home, counsel them on how to actually use their medication.”—Pharmacist 3
“we, the [doctors] may introduce the medication to the patient… but then that gets followed up by
our nurse educators… I think they sort of try to reinforce our initial educational efforts.”—Physician
3
Many physicians stated they were aware that patients and their families want to hear
information from the doctor, not other members of the healthcare team. Nurses also felt that patients
wanted to hear information from the physician.
“Parents and patients—I think, want to hear it from the doc, but I think giving them a different
perspective from somebody else has some real power.”—Physician 2
There was unanimous agreement amongst the healthcare providers that verbal counseling
should be supplemented by additional education materials. There was a split opinion about the
effectiveness of this material, as this content was currently offered as written paper pamphlets.
Dieticians also employ pre- and post-testing material during verbal counseling.
“I think that combined with some of the technology and certainly as I said, the handouts, the
pamphlets, paperwork, things like that. Something tangible.”—Pharmacist 5
“I think most of the pamphlets go in the garbage.”—Nurse 5
3.2.3. Medication Access and Insurance Challenges
All healthcare professionals discussed the challenges people with CF face regarding insurance.
Prior authorizations were described as a major challenge by the healthcare team, and nurses and
pharmacists identified this was something in which pharmacist could assist.
“definitely access. A lot of the times, patients struggle with getting prior authorization or letters of
medical necessity, which oftentimes can delay therapy. Or even maybe as simple as their insurance
will only cover the medication if it’s coming from a specialty pharmacy”—Pharmacist 1
“If we could get more of a pharmacist, we would… I would love for some of the higher-level prior
authorizations to be taken over, too, by the pharmacist.”—Nurse 2
Physicians and nurses also discussed financial burden for people with CF because of the high
cost of medications. Pharmacists also identified medication access challenges regarding the need for
one patient with CF to rely on multiple pharmacies (including specialty pharmacy) to obtain all their
medications.

Pharmacy 2019, 7, 34 6 of 16
“I think they have challenges in terms of expense, they have challenges in terms of getting them
through their insurance, and they have challenges just keeping up with the compliance intake.”—
Physician 6
3.3. Organization
The organizational impact on pharmacist involvement in the CF care team was highlighted by
study participants.
3.3.1. Awareness of Pharmacy Services
Physicians unanimously reported that they rarely interacted with community pharmacies, and
many physicians identified that nurses were the primary point of contact with pharmacists. Most
nurses reported they communicate with outpatient pharmacies daily via telephone conversations.
Dieticians also report working with pharmacists daily, primarily to overcome insurance barriers.
“I don’t always necessarily think their knowledge of CF is as vast as it could be, I mean I know it’s a
very specialized disease. But most of the time, if you provide them with an explanation, they’re
willing to work with you… I’d say I deal with them pretty regularly though. Daily.”—Dietician 1
Existing communication between the CF care team and pharmacists was described as minimal
by physicians. The healthcare team members had some ideas by which this communication could be
improved, such as including pharmacists on rounds.
“It isn’t much. I mean, I’m not going to be judgmental and say the communication is poor. I would
just say that there tends not to be much.”—Physician 5
“I think it’s not even the pharmacists that we need to improve communication with, but the layers
that exist before the pharmacist… when you finally get to that pharmacist, they understand, they
know what you’re talking about and it’s a little easier.”—Nurse 4
3.3.2. Benefits and Drawbacks of Pharmacist Involvement
Pharmacists identified several areas in which they could be helpful, including medication
education and discharge counseling, relieving other care team members’ workload by handling drug-
related issues, and providing private counseling in community pharmacies to improve adherence.
“we can provide a different aspect of monitoring care that the physicians then don’t need to do. So
all the drug level monitoring, some of the compliance monitoring, some of trying to figure out how
to make things taste better, or how to fit them down a G-tube, or how to avoid drug interactions by
spacing certain meds away from each other.”—Pharmacist 6
“I think the most important benefit is—would be number one, education.”—Pharmacist 3
The healthcare team members identified several ways in which pharmacists could contribute to
overall care for patients with CF, including insurance coverage and drug acquisition, refill history,
medication safety, and patient education.
“It would be particularly useful if there were pharmacists always available who could be doing the
tracking and the, making sure that the flow of medications continues through the paperwork and
other hurdles.”—Physician 6
“As the medication regimens are getting more and more complex, we need the expertise of a
pharmacist to help do some of those higher prior authorizations that require a little more knowledge
and data to defend—Nurse 3
Pharmacists anticipated only a few drawbacks of being a member of the healthcare team that
cares for people with CF. The primary concern discussed by several pharmacists was care
coordination and the increased complexity required to uphold good communication practices

Pharmacy 2019, 7, 34 7 of 16
between the care team. Pharmacists also mentioned increased costs for the healthcare system, as
pharmacists were not included in the hospital’s existing financial model.
“I think bringing all parties together so that we’re all working cohesively is probably the biggest
challenge.”—Pharmacist 4
“If you don’t have robust communication with the nursing staff as well as the physician or
collaboration between the three of them, then that can create a serious issue…”—Pharmacist 3
“So not any drawbacks that I can think of other than, possibly, I guess, increased cost of the health
care system. But in the hopes of the program, or the hopes of the CF pharmacist is to reduce costs
elsewhere.”—Pharmacist 1
Members of the CF care team also identified increased financial burden on the hospital to
support pharmacists providing care but were primarily concerned with patients feeling
overwhelmed by having to visit with another member of the healthcare team. The care team was also
concerned that community pharmacists’ knowledge about CF may be limited to properly support
people with CF.
“Our patients meet with four or five team members in every visit, so inserting yet another person
that extends their hours long visit, they just might get tired of seeing so many people.”—Physician
6
“The barriers will include, education. Not every pharmacist is trained in CF… and so, there’s issues
around patient populations, and disease frequency”—Physician 5
“Predominantly money… Resources, limited resources! Space and money. Yeah, and time”—Nurse
3
3.4. Tools and Technologies
Participants discussed the potential for a mobile application to be used as a tool to improve
medication adherence for people with CF. Pharmacists also identified the use of social media as a
tool to communicate with people with CF.
Technologies that Influence Adherence and Prescribing
All healthcare professionals perceived benefit to offering a mobile application for use by people
with CF, though there were differing opinions about the content and purpose of the app. In general,
pharmacists described the app as a tool to support existing medication management techniques.
Physicians thought an app could be helpful for self-management or compliance.
“I always feel that some sort of knowledge center with that has a wealth of videos, a video library that
would be able to, number one show people how to use their medication. Number two, go through the
clinical aspects of the medication. Side effects, storage, and stability.”—Pharmacist 3
“I think it could be very helpful for, perhaps, keeping them on track for when they’re supposed to take
them… as a reminder function, I think it could be very valuable.”—Physician 3
“We’ve had different nutrition apps and we’ve asked people to go home and look at things and that
doesn’t really happen.”—Dietician 1
There were some concerns to offering a mobile application, including effectiveness of a mobile
app as an educational tool, and how the app could be safely offered in clinic, using a communal
device.
“Well, in the clinic setting that’s hard to do on a pad because it has to be sterilized between patients.
And so, we think it’s easier to hand out papers.”—Nurse 2
“In terms of whether they would take the time to actually learn the details of the medicines through
an app, I’m a little skeptical but it might work.”—Physician 6

Pharmacy 2019, 7, 34 8 of 16
Participants were also concerned that a mobile application may not be appropriate for all ages
of people with CF. Pharmacists believe medication education is only successful if patients were
reached in their environment, providing education through blog posts or social media, or preparing
them to explain CF in their own way.
“I think that is targeted—it would definitely be for adolescents, and not necessarily our older
patients.”—Physician 4
“I mean if I’m looking at how old the average patient is, you know, we gotta look where they are. So
you would use the data to suggest, ‘Hey they’re probably on Facebook’…you scroll and you’re
watching and it’s like, everything is in a video. It’s all video digesting content.”—Pharmacist 2
In terms of other medication adherence tools, there was interest among physicians to implement
compliance-tracking devices to install on the patient’s vest.
“We are now instituting a way of determining whether patients are using their vest. There are some
devices that you can plug the vest into, and so you can tell from the electrical current use whether
the device has been turned on or not.”—Physician 5
3.5. Environment
Participants solely discussed external environment factors, including collaborative practice
agreements for pharmacists and issues with care team access to complete refill histories.
3.5.1. Collaborative Practice Agreements
Pharmacist participants advocated for their CF care team involvement as decision-makers
through collaborative practice agreements. Pharmacists had several ideas about what the partnership
between pharmacists and other healthcare professionals could look like, and identified many reasons
this would be beneficial to improve health care for people with CF.
“I think that pharmacists have an opportunity to even go further and be—take part in collaborative
practice agreements… where pharmacists could change the therapy without having direct physician
oversight.”—Pharmacist 1
“We would be a physician extender. So the physician is billing for the services that the pharmacist
provides… we touch these patients multiple times a month.”—Pharmacist 2
3.5.2. Refill History Access
All members of the CF care team rely on refill and dispense histories as their primary method to
tracking medication adherence, and supplement refill history knowledge by discussing medication
adherence with the patient. Physicians also evaluated lung function tests to supplement refill history
and improve their understanding of patient compliance.
“No, not one particular method... you often can tell by their nonverbals, by the look on their face
when you ask them a question… and we have patient fill histories that we can look at.”—Nurse 3
“I always discuss it with the patient to see what barriers there are between them adhering to the
medication and non-adherence… I think it’s very individual.”—Dietician 1
4. Discussion
Despite the benefits that inpatient pharmacists have made in the care of patients with CF,
pharmacists are not required members of the healthcare team at CFF-accredited centers [15–17]. The
perceptions of CF care team participants about where pharmacists could contribute were reported
within the components of the SEIPS model (person, tasks, organization, tools and technologies, and
environment) [14]. This study identified specific opportunities for pharmacists to assist with
medication challenges experienced by people living with CF, including poor medication adherence,
medication counseling, and limited medication access because of barriers such as prior authorizations

Pharmacy 2019, 7, 34 9 of 16
or insurance coverage. Though pharmacists can provide benefit to CF patient care, members of the
CF care team may not fully appreciate the value and contributions pharmacists can provide.
Establishing a team of pharmacists with advanced CF expertise may improve care coordination with
the CF care team and eliminate some of the issues people with CF face regarding medication
management and treatment burden.
Medication adherence due to high medication burden is a serious concern for all members of the
CF care team. Study findings identified several medication challenges for people with CF, with the
CF care team and pharmacists describing treatment management as burdensome, time-consuming,
and complex. The typical medication regimen requires multiple medications in different forms (i.e.,
inhaled, oral, intravenous) to be taken two to three times each day [1,4,6]. Consequently, medication
adherence can be difficult, which has been shown in other studies [1,7]. A recent study found that
recognizing the importance of CF medications is a predominant barrier to patient adherence to
treatment regimens [18]. The pediatric and adolescent population is especially vulnerable. Previous
research has shown that adolescents with CF in particular have low adherence rates which can be
attributed to forgetfulness, being too busy, feeling that treatments give them less freedom, and
believing that skipping treatment is acceptable [19,20]. To monitor adherence, members of the CF
care team frequently consult a patient’s medication refill history, a log that community pharmacists
are responsible for maintaining. Results show the CF care team is aware of pharmacist involvement
in refill history maintenance.
Further complicating medication adherence, medication access is a significant issue experienced
by people with CF; study findings show members of the CF care team are burdened by tasks to
improve access for patients in their care. Some insurance providers will only cover medications from
specialty pharmacies, which do not always stock CF medications. Insurance companies may also only
cover specific medications causing patients with CF to not receive the medications they were
prescribed. In addition, medication cost was an identified concern. Participants stated that some CF
medications from specialty pharmacies cost thousands of dollars and even those covered by
insurance have high copays. The high cost of these medications (i.e., Orkambi
®
, Kalydeco
®
) limits
access to patients with CF [21]. In handling medication access challenges, study participants
explained that issues with prior authorizations were time consuming and caused delays in patients
receiving their CF medications. A previous study found that insurance prominently impacts the
health of patients with CF, where patients who had Medicaid or public insurance had a higher risk
of death while waiting for a lung transplant than those who had private or Medicare insurance [22].
A previous study shows pharmacists are well-positioned to address prior authorization and
insurance coverage challenges that burden existing CF care team workload [23]. Study findings show
the CF care team identified pharmacist assistance with this task as a perceived benefit to the
organization.
The study identified challenges in care coordination and transitions of care for patients with CF.
Pharmacist participants revealed that they are often not included by other healthcare members in the
care of patients with CF even though they see the patients more frequently. The coordination of care
is often difficult due to the many pharmacies that patients with CF use for their medications. CF care
team participants reported they do not expect community pharmacists to have the level of expertise
required to properly educate people with CF, knowing that many community pharmacists have little
contact or opportunity to experience providing care for a patient with CF. This suggests a community
pharmacist’s level of expertise and interaction with nurses and dieticians impacts CF care team
awareness of pharmacy services they can provide. Consequently, as shown in a previous study,
medication reconciliation needs to be prioritized [24]. Pharmacists are easily accessible medication
experts that can provide clinical services to people with chronic conditions such as CF more
frequently than other healthcare professionals [25–27].
Pharmacists are in the community and can provide counseling and education to people living
with CF about their medications or address any barriers. Previous research has shown that
pharmacists involved in CF care have provided patient education on medications and treatment
management, monitored drug-drug interactions, and detected appropriate medication dosing [15].

Pharmacy 2019, 7, 34 10 of 16
Other benefits of pharmacists included in CF care in the inpatient setting include improving
medication monitoring, communication with the multidisciplinary healthcare team, and efficient use
of resources when caring for patients [16,17]. Due to the complexity of CF treatment regimens,
participants recommended that it would be beneficial for the pharmacist to create medication
schedules for patients with CF to avoid drug interactions. Participants also stated that pharmacists
could assess adherence in people with CF by reviewing their medication list and addressing any
issues that arise. In addition, participants recommended that pharmacists address insurance issues
encountered by patients with CF. Outpatient pharmacists within CFF-accredited centers will be well-
positioned to assist patients to navigate insurance issues with prior authorizations, medication access,
and cost. Consequently, this would relieve the burden from the healthcare members at the CFF
accredited center and patients with CF. Pharmacists can also provide medication education to CF
patients. Results from this study suggest that CF patients prefer online learning materials or
interactive technology such as tablets or mobile applications. Previous studies have used smartphone
applications and telehealth to improve adherence in patients with CF and were shown to be feasible
and acceptable [28,29]. Consequently, innovative methods using technology should be implemented
to deliver education to patients with CF.
Limitations
Healthcare members were recruited from one CFF-accredited center, so the results may not
generalizable to all regions. Pharmacists who were knowledgeable about CF were also recruited to
participate in interviews which creates selection bias and cannot be generalizable to all pharmacists.
5. Conclusions
People living with CF experience many medication and pharmacy-related challenges such as
high medication burden, medication access, cost, insurance coverage, and care coordination.
Although pharmacists are not required members of the healthcare team for CFF accredited centers,
this study identified many benefits of having outpatient pharmacists support patients with CF.
Pharmacists can help relieve the medication burden for patients with CF by creating schedules that
avoid drug interactions. Additionally, pharmacists can assist with assessing drug monitoring and
adherence, and assist with insurance issues.
Author Contributions: conceptualization, O.A.; methodology, O.A.; validation, O.A.; formal analysis, O.A. and
A.M.; investigation, O.A.; resources, O.A.; data curation, O.A.; writing—original draft preparation, O.A. and
A.M.; writing—review and editing, O.A. and A.M.; visualization, O.A.; supervision, O.A.; project
administration, O.A.
Funding: This research received no external funding.
Acknowledgments: Daniel Weiner for helping to facilitate data collection and Alison Feathers for assisting in
data collection and analysis.
Conflicts of Interest: The authors declare no conflict of interest.
Appendix A
Appendix A.1. Pharmacist Interview Guide
A. Introductory Questions About Cystic Fibrosis (CF)
1. Can you describe what do you know about CF?
2. What do you know about the healthcare services needed for patients with CF?
3. Have you had experiences providing pharmacy services for patients with CF?
If Yes:
a. Please describe the pharmacy services that were provided.
b. Were there specific medication use challenges that these patients experienced?

Pharmacy 2019, 7, 34 11 of 16
c. Were there specific pharmacy-related problems they experienced? (i.e., access to
medication, insurance, etc.)
d. Were these able to be addressed?
If No:
a. Describe the pharmacy-related needs or problems of CF patients. (May probe for issues
related to access to medications, insurance issues, etc.)
b. What recommendations do you have for addressing these pharmacy-related issues?
4. What do you think are the benefits or drawbacks of pharmacist involvement in the care of
patients with CF?
5. Can you describe how pharmacists could potentially partner with other healthcare professionals
to improve care for patients with CF?
B. Support for People Living With CF
We would like to know more about how pharmacists can support people living with CF.
1. From your experience, what common difficulties do patients have when taking medications for
chronic conditions?
2. Can you describe possible ways pharmacists could assist patients with CF?
(How do you think pharmacists could be equipped to support patients with CF?)
a. Do you think pharmacists can support people living with CF? If so, how?
In what ways can community pharmacists uniquely support people with CF?
C. Preferences for Medication Education
We would like to know more about how you think people living with CF should be educated
about their medications.
1. How do you think a patient using medication for CF should be educated on his/her condition
and medication regimen?
a. How often do you think a patient using medication for CF should be educated about taking
his/her medications correctly?
2. If you have provided medication education for patients with CF, what types of educational
materials have you used?
If No: What types of education materials have you used with patients with other types of chronic
conditions?
3. What types of education materials do you think would be most helpful for providing medication
education for patients with CF?
4. Assuming patients want information about their medications, how do you think patients prefer
to receive education about their medications?
Probe for different educational methods (one-on-one counseling with the pharmacist, written
materials/pamphlets, interactive technology like on an iPad, videos on the Internet or TV, using
an app on a smartphone or tablet)
5. Do you think patients with CF would be interested in using an app, like on a smartphone or
tablet, to learn about his/her medicines and self-management? If so, why?
If Yes:
a. How do you think an app could help patients with CF to learn about their medicines and
self-management?
b. What features and content do you think would be beneficial to the app design?
6. Of the methods we discussed, which do you believe is the most effective method for delivering
education to patients at a community pharmacy?
D. Pharmacist Counseling

Pharmacy 2019, 7, 34 12 of 16
We will now ask you about providing medication counseling for people living with CF.
1. How do you feel about talking to patients with CF about their medications?
2. Can you describe potential ways that pharmacists could be better equipped to provide
medication counseling for people living with CF?
3. How do the elements of the pharmacy (waiting area, space) facilitate or impede counseling to
patients with CF?
(If not discussed) Please describe any changes you believe would help.
4. Can you describe other ways to engage younger CF patients in medication use discussions?
Do you have anything you’d like to add before we end?
Appendix A.2. Other Healthcare Team Members Interview Guide
A. Introductory Questions
1. Tell me about what you do in your CF care center.
2. Describe the pharmacy-related needs or problems of CF patients. (May probe for issues related
to access to medications, insurance issues, etc.)
3. What kinds of challenges do you think that CF patients face regarding the use of CF medications?
4. What types of medications or treatments seem to be especially hard for CF patients to administer
or adhere to correctly?
5. What method(s) do you use to assess if patients are adhering to their medication regimens?
6. What recommendations do you have for addressing these medication or pharmacy-related
issues?
B. Medication Education
We would like to ask you about providing adolescent or young adults (AYA) with CF
information about their medicines.
1. Have you provided any form of medication education to patients with CF?
a. If Yes: Please describe what information was provided (i.e., drug information, dosing, side
effects, etc.) and how often you provided medication education.
b. What steps do you take to make sure the patient with CF has understood the medication
information you provided?
2. How well do you think that patients with CF are educated on their medications?
a. How can their knowledge about medicines be improved?
3. Who do you think should be educating patients with CF on their medications? (Probe for doctor,
pharmacist, nurse, etc.)
4. Assuming patients want to learn about their medications, how do you think patients with CF
prefer to learn about their medications? (Probe for one-on-one counseling with the
pharmacist/doctor/nurse, written materials/pamphlets, interactive technology like on an iPad,
videos on the Internet or TV, using an app on a smartphone or tablet)
5. Do you think patients with CF would be interested in using an app, like on a smartphone or
tablet, to learn about his/her medicines and self-management? If so, why?
a. If Yes: How do you think an app could help patients with CF to learn about their medicines
and self-management?
b. What features and content do you think would be beneficial to the app design?
6. Are there any other ways that you can think of that would be helpful for patients with CF to
learn about their medicines?
C. Experiences with Outpatient, Specialty, and Community Pharmacists
We would now like to ask you some questions about your experiences with outpatient and
community pharmacists.

Pharmacy 2019, 7, 34 13 of 16
1. How often and in what practice setting (i.e., in-patient, outpatient, community pharmacies such
as Giant Eagle, Rite Aid, CVS, Walgreen’s, etc.) do you interact with pharmacists involved in the
care of patients with CF?
2. How would you describe the communication between pharmacists and other CF healthcare
team members?
3. Can you describe any possible ways to improve communication between the healthcare team
members and pharmacists?
4. How do you think pharmacists can support the other members of the healthcare team providing
care for people with CF?
5. What challenges with treatment and medications do you think pharmacists could possibly
address for patients with CF?
6. Do you think there are any barriers to pharmacist involvement in the care of patients with CF?
a. If so, what kinds of barriers?
7. Do you think there would be any benefits by implementing outpatient pharmacy services in
your CF center?
a. If so, what benefits?
8. Do you think there are there any barriers to implementing outpatient pharmacy services?
a. If so, what kinds of barriers?
9. Do you think community pharmacists can uniquely support patients with CF? (Pharmacists
practicing at Giant Eagle, Rite Aid, CVS, Walgreen’s, etc.) If so, how?
Do you have anything you’d like to add before we end?
Appendix B
Table A1. Themes, subthemes, and verbatim quotes from participant interviews.
Work System
Components and
Themes
Additional Verbatim Quotes
Person(s)
Experience and
Expertise Caring for
People with CF
“CF is an autosomal recessive disorder essentially where, in a nutshell, you have these CFTR
mutations where secretions in different mutli-organ systems become thick… oftentimes
leading to lung transplant later on down the road. But it also affects the liver, pancreas, and
then also male reproductive systems. So it’s multi-organ disease.”—Pharmacist 1
“I’ve been able to provide probably only to about two patients that we’ve had with CF—well
actually, one with CF”—Pharmacist 3
“I do cover the pulmonology service on the floors. I do all their pharmacokinetics for all their
levels, I help them pick the antibiotics, I make sure all their meds are right, I help with their
prescriptions, writing them and whatever, if they ever need me to go in and talk to them
about something, I certainly would be able to do so”—Pharmacist 6
Tasks
Medication
Management
Burden
“the challenging administration options for the administration options for the medications as
most of them are inhaled, oftentimes have to do them 3 times a day—to 2 times a day… so it
takes up a large portion of these patients’ time”—Pharmacist 1
“I think Cayston
®
… but it’s a three time a day medication. So, I think even though it only
takes three minutes to nebulize, it’s three times a day. I find that patients don’t do
medications three times a day. Tobi tends to take between twenty minutes and a half an hour
to nebulize… even though it’s only every other month, they tend to struggle in those months
because it’s an added medication to their day. They seem to be able to get Pulmozyme
®
in,
although when they travel it’s hard because it’s a refrigerated medication. And then

Pharmacy 2019, 7, 34 14 of 16
HyperSal
®
is twice a day and it makes you cough, so—and it tastes bad, so some of the
patients don’t want to use the Hyper-Sal because it makes you cough.”—Nurse 4
“I think that one of the main difficulties is just remembering to take the medication… a lot of
times patients can get busy and forget to take those dosing of the medications. I think
sometimes too, particularly with antibiotics, patients start feeling really well and they decide
not to take their medications after they start feeling well. And then on the flip side of things,
you can also have patients feel not so well, and they think that their medications are
contributing to their poor state and decide not to take their medications.”—Pharmacist 1
“I know that there are medication use challenges that they do experience because they are
children. They are not as familiar with how to use a nebulizer. It can be challenging to
them.”—Pharmacist 3
Medication
Education
“We don’t necessarily expect any local pharmacy, brick and mortar I’m referring to, to do
patient teaching for their meds. It’s too complex, too specialized.”—Nurse 3
“I think most people learn best from one on one counseling. If you give someone written
materials, it’s more likely than not that they will not be read… we’re very careful about
education in our clinic. And we have a dedicated person call a nurse educator… and they
tend to meet with the families and go over the finer points about the medications.”—
Physician 5
“For our end, with the kind of quiz that we’re doing, that’s actually geared more towards our
transition patients, so patients going from teens to adults. I think it’s really important”—
Dietician 1
Medication Access
and Insurance
Challenges
“So, the pharmacy said the medication was denied, then we have to reach out to the
insurance company and do a prior auth… if the auth is denied, then we do the appeal… if we
can’t get the appeal, then we have to have our physician reach out. We don’t handle the
enzyme authorizations or the supplements. We have a dietician that does those.”—Nurse 1
“The drugs can be astonishingly expensive. Some as much as $306,000 a year for Kalydeco
for example.”—Physician 5
“coordinating all the prescriptions, right? There’s a lot of fragmentation, right? They’re
going to maybe two, three, four pharmacies to get their medicine. And just managing that is
a burden.”—Pharmacist 2
Organization
Awareness of
Pharmacy-Related
Needs
“They can help with anti-microbial management looking at past cultures and… helping
physicians and nurses decide which anti-microbial regiments would be best for the patient
to—as to not limit our options for future use based on antimicrobial resistance.”—
Pharmacist 1
Benefits and
Drawbacks of
Pharmacist
Involvement
“It’s just infuriating to find out that we think we gave a patient an antibiotic, which was
prescribed, and find out eight days later that they haven’t gotten it yet because of insurance
hoops, prior authorizations… They’re little snags, but they result in devastating
consequences. So, those are all things that a pharmacist can help us with.”—Nurse 3
“more education, maybe more safety for the patients, better outcomes for the patient.”—
Dietician 2
“Sometimes we go in and we review their medications when they first come into clinic and
we go over what they’re taking. I think if there was a more in-depth conversation.”—Nurse 1
“I think that our nutritionist would like him [the pharmacist] to help in… helping with
patients who are interested in our herbal remedies. And what are the food and drug
interactions.”
—
Nurse 5
Tools and Technologies
Technologies that
Influence Adherence
and Prescribing
“we used to call all the pharmacists and order them, so we had more interaction than we do
now. Now with the electronic medical record and electronic e-prescribing, we have much less
interaction. And I find that we probably have, maybe some or more delays to patients getting
their meds because of that.”—Nurse 2

Pharmacy 2019, 7, 34 15 of 16
“I think that video presentations with graphics followed by a quiz is probably the best way to
do it so that they learn and then have to self-reflect and then spit out what the answers
are.”—Physician 1
“I think—specifically for young people, videos, apps… some sort of content like that, they
can watch it at their own time, rewatch to understand a missing point. And then make notes
and reach out to us like, ‘Hey I watched this, and these are the questions I have.’”—
Pharmacist 4
“I think that we have a lot online now and we have iPads… that’s what kids really like. They
want to see something online”—Nurse 3
Environment
Collaborative
Practice Agreements
“I think that we can help them to streamline some of their therapies, or make adjustments,
additions and subtractions, like discontinuations of things as they progress through.”—
Pharmacist 7
Refill History Access
“Well a lot of the pharmacies are set up, especially with the expensive drugs, it seems they
try to track them more because they have a vested interest to do so. So, we’ll get reminder
calls.”—Nurse 2
“[the pharmacists] call us—I think that’s a generous—you know, for refills, they’ll call us,
or fax for refills and I think that helps families. Some of the pharmacists call for medication
lists because they are kind of keeping an eye on what the family is getting and sending
automatic refills to the family.”—Nurse 4
“The most effective test we have right now is lung function testing. And lung function
testing is kind of the final common pathway for all therapies. To say if your lungs are good
then you must be doing the right thing.”
—
Physician 5
References
1. Sawicki, G.S.; Tiddens, H. Managing treatment complexity in cystic fibrosis: Challenges and opportunities.
Pediatr. Pulmonol. 2012, 47, 523–533.
2. Cystic Fibrosis Foundation: About Cystic Fibrosis. Available online: https://www.cff.org/What-is-
CF/About-Cystic-Fibrosis/ (accessed on 1 December 2018).
3. Autosomal recessive inheritance | My46. Available online: https://www.my46.org/intro/autosomal-
recessive-inheritance (accessed on 25 February 2019).
4. Quittner, A.L.; Saez-Flores, E.; Barton, J.D. The psychological burden of cystic fibrosis. Curr. Opin. Pulm.
Med. 2016, 22, 187–191.
5. Cystic Fibrosis Foundation: 2016 Patient Registry Reports. Available online:
https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2016-Patient-Registry-Reports/
(accessed on 1 December 2017).
6. Cystic Fibrosis Foundation: Treatments and therapies. Available online: https://www.cff.org/Life-With-
CF/Treatments-and-Therapies/ (accessed on 1 December 2017).
7. Goodfellow, N.A.; Hawwa, A.F.; Reid, A.J.; Horne, R.; Shields, M.D.; McElnay, J.C. Adherence to treatment
in children and adolescents with cystic fibrosis: A cross-sectional, multi-method study investigating the
influence of beliefs about treatment and parental depressive symptoms. BMC Pulm. Med. 2015, 15, 43.
8. Cystic Fibrosis Foundation: Care centers. Available online: https://www.cff.org/Care/Care-Centers/
(accessed on 1 December 2017).
9. Cystic Fibrosis Foundation: Your CF care team. Available online: https://www.cff.org/Care/Your-CF-Care-
Team/ (accessed on 1 December 2017).
10. Kerem, E.; Conway, S.; Elborn, S.; Heijerman, H. Standards of care for patients with cystic fibrosis: A
European consensus. J. Cyst. Fibros. 2005, 4, 7–26.
11. Geiss, S.K.; Hobbs, S.A.; Hammersley-Maercklein, G.; Kramer, J.C.; Henley, M. Psychosocial factors related
to perceived compliance with cystic fibrosis treatment. J. Clin. Psychol. 1992, 48, 99–103.
12. Cystic Fibrosis Trus: Consensus documents. Available online: https://www.cysticfibrosis.org.uk/en/the
work we do/clinical care/consensus documents (accessed on 24 February 2019).
13. Bell, S.C.; Robinson, P.J.; Fitzgerald, D.A. Cystic Fibrosis Standards of Care, Australia; Johns Hopkins
University: Baltimore, MA, USA, 2008; p. 76.

Pharmacy 2019, 7, 34 16 of 16
14. Holden, R.J.; Carayon, P.; Gurses, A.P.; Hoonakker, P.; Hundt, A.S.; Ozok, A.A.; Rivera-Rodriguez, A.J.
SEIPS 2.0: A human factors framework for studying and improving the work of healthcare professionals
and patients. Ergonomics 2013, 56.
15. Sterner-Allison, J.L. Management of adolescent and adult inpatients with cystic fibrosis. Am. J. Health Syst.
Pharm. 1999, 56, 158–160.
16. Redfern, J.; Webb, A.K. Benefits of a dedicated cystic fibrosis pharmacist. J. R. Soc. Med. 2004, 97, 2–7.
17. Cies, J.J.; Varlotta, L. Clinical pharmacist impact on care, length of stay, and cost in pediatric cystic fibrosis
(CF) patients. Pediatr. Pulmonol. 2013, 48, 1190–1194.
18. Lewis, K.L.; John, B.; Condren, M.; Carter, S.M. Evaluation of Medication-related Self-care Skills in Patients
With Cystic Fibrosis. J. Pediatr. Pharmacol. Ther. 2016, 21, 502–511.
19. Modi, A.C.; Quittner, A.L. Barriers to Treatment Adherence for Children with Cystic Fibrosis and Asthma:
What Gets in the Way? J. Pediatr. Psychol. 2006, 31, 846–858.
20. Dziuban, E.J.; Saab-Abazeed, L.; Chaudhry, S.R.; Streetman, D.S.; Nasr, S.Z. Identifying barriers to
treatment adherence and related attitudinal patterns in adolescents with cystic fibrosis. Pediatr. Pulmonol.
2010, 45, 450–458.
21. Ferkol, T.; Quinton, P. Precision Medicine: At What Price? Am. J. Respir. Crit. Care Med. 2015, 192, 658–659.
22. Krivchenia, K.; Tumin, D.; Tobias, J.D.; Hayes, D. Increased Mortality in Adult Cystic Fibrosis Patients with
Medicaid Insurance Awaiting Lung Transplantation. Lung 2016, 194, 799–806.
23. Abraham, O.; Li, J.S.; Monangai, K.E.; Feathers, A.M.; Weiner, D. The pharmacist’s role in supporting
people living with cystic fibrosis. J. Am. Pharm. Assoc. 2018, 58, 246–249.
24. Horace, A.E.; Ahmed, F. Polypharmacy in pediatric patients and opportunities for pharmacists’
involvement. Integr. Pharm. Res. Pract. 2015, 4, 113–126.
25. McInnis, T. Get the medications right: A nationwide snapshot of expert practices—Comprehensive
medication management in ambulatory/community pharmacy. Health2 Resour. 2016, 7.
26. Giberson, S.; Yoder, S.; Lee, M. Improving Patient and Health System Outcomes through Advanced Pharmacy
Practice: A Report to the U. S. Surgeon General; U.S. Public Health Service: Washington, D.C., USA, 2011.
27. National Center for Chronic Disease Prevention and Health Promotion: A program guide for public health:
Partnering with the pharmacist in the prevention and control of chronic diseases. Available online:
https://www.cdc.gov/dhdsp/programs/spha/docs/pharmacist_guide.pdf (accessed on 24 February 2019).
28. Wood, J.; Jenkins, S.; Putrino, D.; Mulrennan, S.; Morey, S.; Cecins, N.; Hill, K. High usability of a
smartphone application for reporting symptoms in adults with cystic fibrosis. J. Telemed. Telecare 2018, 24,
547–552, doi:10.1177/1357633X17723366.
29. Gur, M.; Nir, V.; Teleshov, A.; Bar-Yoseph, R.; Manor, E.; Diab, G.; Bentur, L. The use of telehealth (text
messaging and video communications) in patients with cystic fibrosis: A pilot study. J. Telemed. Telecare
2017, 23, 489–493.
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open
access article distributed under the terms and conditions of the Creative Commons
Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).